1-5 of 5
January Baron
Close
Sort by
Journal Articles

Ocular Health of Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Data from the DREAMM-2 Trial of Belantamab Mafodotin (Belamaf)

Rakesh Popat, Aikaterini Kazantzi, MD, Asim Farooq, MD, Praneetha Thulasi, MD, Sagar Lonial, MD FACP, Andrzej Jakubowiak, MD PhD, Ashraf Z. Badros, MD, Bennie H. Jeng, MD, Joanna Opalinska, MD, January Baron, MS, Trisha Piontek, BSN, Julie Byrne, PhD, Lynsey Womersley, MSc, Ira Gupta, MD, Simona Degli Esposti, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 43–44.
https://doi.org/10.1182/blood-2020-139315
Published: 2020
Journal Articles

Infusion-Related Reactions (IRRs) in the DREAMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Ajay Nooka, MDMPH, Hans C. Lee, MD, Ashraf Z. Badros, MD, Peter Voorhees, MD, Malin Hultcrantz, MD PhD, Lionel Karlin, MD, Bertrand Arnulf, MD, Paul G. Richardson, MD, Eric Zhi, PhD, January Baron, MS, Trisha Piontek, BSN, Eric Lewis, MD, Joanna Opalinska, MD PhD, Ira Gupta, MD, Adam D. Cohen, MD, Sagar Lonial, MD FACP
Journal: Blood
Blood (2020) 136 (Supplement 1): 22–23.
https://doi.org/10.1182/blood-2020-139687
Published: 2020
Journal Articles

Recovery of Ocular Events with Longer-Term Follow-up in the DREAMMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Sagar Lonial, MD FACP, Ajay Nooka, MDMPH, Praneetha Thulasi, MD, Ashraf Z. Badros, MD, Bennie H. Jeng, MD, Natalie S. Callander, MD, Douglas Sborov, MD MS, Brian E. Zaugg, MD, Rakesh Popat, Simona Degli Esposti, MD, Julie Byrne, PhD, Joanna Opalinska, MD PhD, January Baron, MS, Trisha Piontek, BSN, Ira Gupta, MD, Reza Dana, MD MSc, MPH, Asim Farooq, MD, Andrzej Jakubowiak, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 26–27.
https://doi.org/10.1182/blood-2020-140078
Published: 2020
Journal Articles

A Phase I Study of GSK525762, a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of Phase I/II Open Label Single Agent Study in Patients with Acute Myeloid Leukemia (AML)

Mark Dawson, MD PhD, Eytan M. Stein, MD, Brian J.P Huntly, Anastasios Karadimitris, PhD, Manali Kamdar, Carlos Fernandez de Larrea, Michael J. Dickinson, Paul Sung-Hao Yeh, MBBS, FRCPA, FRACP, Naval Daver, MD, Aristeidis Chaidos, MD PhD, Martin S. Tallman, MD, Raquel Jiménez, MD, Thierry Horner, PhD, January Baron, MS, John Brennan, Geraldine Ferron-Brady, Yuehui Wu, PhD, Natalie Karpinich, Brandon Kremer, Arindam Dhar, MBBS,MDPhD, Gautam Borthakur, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1377.
https://doi.org/10.1182/blood.V130.Suppl_1.1377.1377
Published: 2017
Journal Articles

A Phase I/II Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Subjects with Relapsed, Refractory Hematologic Malignancies

Gautam Borthakur, MD, Mark A Dawson, MD PhD, Eytan M. Stein, MD, Anastasios Karadimitris, Brian J.P Huntly, MD PhD, Michael J. Dickinson, MBBS, FRACP, FRCPA, Aristeidis Chaidos, Thierry Horner, PhD, John Brennan, January Baron, Brandon E. Kremer, MD PhD, Arindam Dhar, MBBS, MD PhD
Journal: Blood
Blood (2016) 128 (22): 5223.
https://doi.org/10.1182/blood.V128.22.5223.5223
Published: 2016